Do molecularly targeted agents in oncology have reduced attrition rates?
- PMID: 19008887
- DOI: 10.1038/nrd2758
Do molecularly targeted agents in oncology have reduced attrition rates?
Similar articles
-
Mea Culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine.Expert Rev Mol Diagn. 2009 Apr;9(3):217-21. doi: 10.1586/erm.09.7. Expert Rev Mol Diagn. 2009. PMID: 19379079 No abstract available.
-
Envisioning the future of early anticancer drug development.Nat Rev Cancer. 2010 Jul;10(7):514-23. doi: 10.1038/nrc2870. Epub 2010 Jun 10. Nat Rev Cancer. 2010. PMID: 20535131 Review.
-
The role of the fDA in cancer clinical trials.Cancer Treat Res. 2007;132:51-109. doi: 10.1007/978-0-387-33225-3_4. Cancer Treat Res. 2007. PMID: 17305017 Review. No abstract available.
-
Are targeted therapies really targeted?Clin Adv Hematol Oncol. 2003 Dec;1(12):722-3. Clin Adv Hematol Oncol. 2003. PMID: 16258475 No abstract available.
-
The seamless approach to drug development in oncology.Clin Adv Hematol Oncol. 2016 Dec;14(12):958-959. Clin Adv Hematol Oncol. 2016. PMID: 28212356 No abstract available.
Cited by
-
Busting the Breast Cancer with AstraZeneca's Gefitinib.Adv Pharmacol Pharm Sci. 2023 Dec 4;2023:8127695. doi: 10.1155/2023/8127695. eCollection 2023. Adv Pharmacol Pharm Sci. 2023. PMID: 38090376 Free PMC article. Review.
-
Market Access Advancements and Challenges in "Drug-Companion Diagnostic Test" Co-Development in Europe.J Pers Med. 2015 Jun 12;5(2):213-28. doi: 10.3390/jpm5020213. J Pers Med. 2015. PMID: 26075972 Free PMC article. Review.
-
The (un)targeted cancer kinome.Nat Chem Biol. 2010 Mar;6(3):166-169. doi: 10.1038/nchembio.297. Nat Chem Biol. 2010. PMID: 20154661 No abstract available.
-
Patient burden and clinical advances associated with postapproval monotherapy cancer drug trials: a retrospective cohort study.BMJ Open. 2020 Feb 17;10(2):e034306. doi: 10.1136/bmjopen-2019-034306. BMJ Open. 2020. PMID: 32071183 Free PMC article.
-
Trends in kinase drug discovery: targets, indications and inhibitor design.Nat Rev Drug Discov. 2021 Nov;20(11):839-861. doi: 10.1038/s41573-021-00252-y. Epub 2021 Aug 5. Nat Rev Drug Discov. 2021. PMID: 34354255 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources